These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

688 related articles for article (PubMed ID: 29689025)

  • 1. COMBINATION THERAPY OF INTRAVITREAL RANIBIZUMAB AND SUBTHRESHOLD MICROPULSE PHOTOCOAGULATION FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION: 6-MONTH RESULT.
    Terashima H; Hasebe H; Okamoto F; Matsuoka N; Sato Y; Fukuchi T
    Retina; 2019 Jul; 39(7):1377-1384. PubMed ID: 29689025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of ranibizumab and subthreshold micropulse laser in treatment of macular edema secondary to branch retinal vein occlusion.
    Buyru Özkurt Y; Akkaya S; Aksoy S; Şimşek MH
    Eur J Ophthalmol; 2018 Nov; 28(6):690-696. PubMed ID: 29696993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial.
    Song S; Yu X; Zhang P; Gu X; Dai H
    BMC Ophthalmol; 2020 Jun; 20(1):241. PubMed ID: 32560639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema.
    Goel S; Kumar A; Ravani RD; Chandra P; Chandra M; Kumar V
    Indian J Ophthalmol; 2019 Jul; 67(7):1105-1108. PubMed ID: 31238421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macular vessel reduction as predictor for recurrence of macular oedema requiring repeat intravitreal ranibizumab injection in eyes with branch retinal vein occlusion.
    Hasegawa T; Takahashi Y; Maruko I; Kogure A; Iida T
    Br J Ophthalmol; 2019 Oct; 103(10):1367-1372. PubMed ID: 30514711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
    Pichi F; Elbarky AM; Elhamaky TR
    Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Ranibizumab and Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusions in Routine Clinical Practice.
    Khan M; Wai KM; Silva FQ; Srivastava S; Ehlers JP; Rachitskaya A; Babiuch A; Deasy R; Kaiser PK; Schachat AP; Yuan A; Singh RP
    Ophthalmic Surg Lasers Imaging Retina; 2017 Jun; 48(6):465-472. PubMed ID: 28613352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab versus bevacizumab and macular grid photocoagulation for macular edema in eyes with non-ischemic branch retinal vein occlusion: results from a prospective randomized study.
    Callizo J; Atili A; Striebe NA; Bemme S; Feltgen N; Hoerauf H; Bertelmann T
    Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):913-920. PubMed ID: 30610424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between short- and long-term effects of intravitreal ranibizumab therapy on macular edema after branch retinal vein occlusion: a prospective observational study.
    Minami Y; Nagaoka T; Ishibazawa A; Yoshida A
    BMC Ophthalmol; 2017 Jun; 17(1):90. PubMed ID: 28610573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
    Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
    Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion.
    Son BK; Kwak HW; Kim ES; Yu SY
    Korean J Ophthalmol; 2017 Jun; 31(3):209-216. PubMed ID: 28471106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
    Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
    Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of subthreshold micropulse laser photocoagulation therapy versus anti-vascular endothelial growth factor therapy for refractory macular edema secondary to non-ischemic branch retinal vein occlusion.
    Feng X; Li Y; Wu M; Dan A; Yang W; Peng Y; Xiao L
    J Int Med Res; 2023 Aug; 51(8):3000605231194462. PubMed ID: 37652453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing ranibizumab, dexamethasone implant, and combined therapy for macular edema secondary to branch retinal vein occlusion: a clinical trial.
    Meng L; Yang M; Jiang X; Li Y; Han X
    Int Ophthalmol; 2024 Jun; 44(1):262. PubMed ID: 38913192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting recurrences of macular edema due to branch retinal vein occlusion during anti-vascular endothelial growth factor therapy.
    Suzuki M; Nagai N; Minami S; Kurihara T; Kamoshita M; Sonobe H; Watanabe K; Shinoda H; Tsubota K; Ozawa Y
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):49-56. PubMed ID: 31732812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with intravitreal bevacizumab and macular grid and scatter laser photocoagulation in patients with macular edema secondary to branch retinal vein occlusion.
    Yang CS; Liu JH; Chung YC; Chou YB; Hung KH
    J Ocul Pharmacol Ther; 2015 Apr; 31(3):179-85. PubMed ID: 25715024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.
    Li F; Sun M; Guo J; Ma A; Zhao B
    Curr Eye Res; 2017 Aug; 42(8):1174-1178. PubMed ID: 28441077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
    Ozkaya A; Tarakcioglu HN; Tanir I
    Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections.
    Osaka R; Muraoka Y; Miwa Y; Manabe K; Kobayashi M; Takasago Y; Ooto S; Murakami T; Suzuma K; Iida Y; Tsujikawa A
    Ophthalmologica; 2018; 239(1):27-35. PubMed ID: 28946138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OPTICAL COHERENCE TOMOGRAPHY PREDICTORS OF SHORT-TERM VISUAL ACUITY IN EYES WITH MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL CONBERCEPT.
    Tang F; Qin X; Lu J; Song P; Li M; Ma X
    Retina; 2020 Apr; 40(4):773-785. PubMed ID: 30640282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.